Introduction: Cannabis sativa is a plant species with numerous active principles, so the list of its therapeutic uses is expanding. In this sense, there are numerous evidences of the possible medicinal use of terpenes, as well as their synergism with cannabinoids (entourage effect). Thus, as more countries contemplate the legalization and authorization of medical cannabis, the number of cannabis extraction and analysis laboratories is increasing to meet the demand, requiring adequate analytical tools.
Methodology: In response to numerous inquiries from physicians, analytical laboratories and users, the PROBIEN chromatography laboratory has selected two methods for the analysis of terpenes in Cannabis oil by gas chromatography technique (GC-FID). The methods are described using HP-5 and Innowax columns. The external standard method was used for the quantitative determination of β-Pinene, Myrcene, p-Cymene, Limonene, Linalool, α-Terpineol, Nerol and Geraniol.
Results: good peak separation and reproducibility were observed, appropriate for the identification and quantification of the main terpenes in Cannabis extracts. The area/concentration ratio was linear in the range of 0.0005 to 2.0 mg/ml.
Main Conclusion: The described methods allow the identification and quantification of the major terpenes in Cannabis oil for an adequate quality control.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443410 | PMC |
http://dx.doi.org/10.31053/1853.0605.v80.n2.39593 | DOI Listing |
JAMA Netw Open
January 2025
Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego.
Importance: The degree that in-home cannabis smoking can be detected in the urine of resident children is unclear.
Objective: Test association of in-home cannabis smoking with urinary cannabinoids in children living at home.
Design, Setting, And Participants: This cross-sectional study used baseline data from Project Fresh Air, a 2012-2016 randomized clinical trial to reduce fine particulate matter levels.
BMC Complement Med Ther
January 2025
Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Background: Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer's disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuroprotective and anti-inflammatory properties. In CBD research, PE is underutilized too.
View Article and Find Full Text PDFCompr Rev Food Sci Food Saf
January 2025
Department of Forest Biomaterials, North Carolina State University, Raleigh, North Carolina, USA.
This review focuses on antimicrobial packaging for food safety, critically examining the activity and efficacy of cannabinoids against commonly found microorganisms and exploring their antimicrobial mechanisms. Specifically, the review considers cannabinoids derived from industrial hemp plants, which are characterized by low levels of psychoactive components. It also outlines viable strategies to control the sustained release of cannabinoids from the packaging, enabling extended storage and enhanced safety of food products.
View Article and Find Full Text PDFBMC Plant Biol
January 2025
Department of Plant Sciences, University of California, Davis, CA, USA.
Background: Future breeding and selection of Cannabis sativa L. for both drug production and industrial purposes require a source of germplasm with wide genetic variation, such as that found in wild relatives and progenitors of highly cultivated plants. Limited directional selection and breeding have occurred in this crop, especially informed by molecular markers.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Pharmaceutics, University of Washington School of Pharmacy, Seattle, WA, USA.
Prenatal cannabis use is associated with neurodevelopmental deficits, likely due to exposure to the psychoactive cannabinoid, (-)-Δ-tetrahydrocannabinol, and its active metabolite, (±)-11-OH-Δ-tetrahydrocannabinol. To determine causality, preclinical studies mimicking human fetal cannabinoid exposure must be conducted. Here we show cannabinoid concentrations across gestation in maternal plasma and paired fetal tissues in trimester 1 and 2 and maternal plasma and fetal umbilical venous plasma in trimester 3.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!